This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Antibody therapy reverses biological signatures of COVID-19 progression (preprint)
medrxiv; 2021.
ما قبل الطباعة
ي الانجليزية
| medRxiv | ID: ppzbmed-10.1101.2021.12.21.21268197
ABSTRACT
Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 11 to placebo or to sotrovimab, a monoclonal antibody for the treatment of SARS-CoV-2 infection. Several laboratory parameters identified study participants at greater risk of severe disease, including a high neutrophil-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test and whole blood transcriptome profiles. Sotrovimab treatment in these groups was associated with normalization of NLR and the transcriptomic profile, and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provided the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identified a 10-gene signature with similar predictive accuracy. In summary, we identified markers of risk for disease progression and demonstrated that normalization of these parameters occurs with antibody treatment of established infection.
النص الكامل:
متاح
مجموعة:
المطبوعات المسبقة
قاعدة البيانات:
medRxiv
الموضوع الرئيسي:
COVID-19
اللغة:
الانجليزية
السنة:
2021
نوع:
ما قبل الطباعة
المراجع ذات الصلة
MEDLINE
...
LILACS
LIS